Immunotherapy in neuromuscular disorders: Current and future strategies

Research output: Contribution to journalArticle

Abstract

Autoimmune mechanisms have recently been implicated in the pathogenesis of an increasing number of neuromuscular diseases. Many of these diseases can be treated with immunotherapeutic agents that are currently available-often with striking success. However, lack of specificity and adverse side effects impose limits on the effectiveness of these immunosuppressive treatments. This article reviews the basic principles of autoimmunity and immune tolerance, and outlines strategies that produce (a) generalized immunosuppression; (b) 'selective' immunotherapy; and (c) 'antigen-specific' immunotherapy. General immunosuppressive treatments, which are the ones most commonly used in current practice, down-regulate the immune system at multiple levels in 'shotgun' fashion. The agents described here include: adrenal corticosteroids, azathioprine, cyclophosphamide, chlorambucil, methotrexate, total lymphoid irradiation, plasmapheresis, and intravenous immunoglobulin. 'Selective' immunotherapeutic strategies are designed to interfere with mechanisms intrinsic to the immune system. Agents that are now being used clinically, or are in advanced stages of development include: cyclosporin A, which interferes with synthesis of the cytokine interleukin 2 (IL2); IL2 toxin, which binds to IL2 receptors on activated T cells, is endocytosed, and kills the cells; and CTLA4Ig, which blocks costimulatory molecules, thus preventing full activation of T cells. We have found that combinations of the selective agents may enhance their effectiveness. 'Specific' strategies are designed to inactivate or suppress antigen-specific T cells. Oral administration of autoantigens has been shown to prevent experimental autoimmune diseases specifically, but the conditions required to suppress ongoing autoimmune diseases are capricious, and depend on many factors. Finally, we describe a method that is still in the experimental stage, which is designed to modify the individual's own antigen-presenting cells so that they will target and inactivate antigen-specific T cells, and thereby turn off the specific autoimmune response. Currently available immunosuppressive methods can now be used successfully to treat many autoimmune neuromuscular diseases, and the application of selective and specific immunotherapeutic strategies promises more precise and effective treatment in the future.

Original languageEnglish (US)
Pages (from-to)1239-1251
Number of pages13
JournalMuscle and Nerve
Volume19
Issue number10
DOIs
StatePublished - 1996

Fingerprint

Immunotherapy
Immunosuppressive Agents
Autoimmune Diseases
T-Lymphocytes
Neuromuscular Diseases
Autoimmunity
Antigens
Immune System
Lymphatic Irradiation
Chlorambucil
Immune Tolerance
Plasmapheresis
Interleukin-2 Receptors
Intravenous Immunoglobulins
Autoantigens
Azathioprine
Firearms
Antigen-Presenting Cells
Endocytosis
Methotrexate

Keywords

  • anergy
  • autoimmunity
  • immune therapy
  • immunosuppression
  • myasthenia gravis
  • neuromuscular diseases
  • suppression
  • tolerance

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Immunotherapy in neuromuscular disorders : Current and future strategies. / Drachman, Daniel B.

In: Muscle and Nerve, Vol. 19, No. 10, 1996, p. 1239-1251.

Research output: Contribution to journalArticle

@article{963312c129764baf86d50f5005b5f3c2,
title = "Immunotherapy in neuromuscular disorders: Current and future strategies",
abstract = "Autoimmune mechanisms have recently been implicated in the pathogenesis of an increasing number of neuromuscular diseases. Many of these diseases can be treated with immunotherapeutic agents that are currently available-often with striking success. However, lack of specificity and adverse side effects impose limits on the effectiveness of these immunosuppressive treatments. This article reviews the basic principles of autoimmunity and immune tolerance, and outlines strategies that produce (a) generalized immunosuppression; (b) 'selective' immunotherapy; and (c) 'antigen-specific' immunotherapy. General immunosuppressive treatments, which are the ones most commonly used in current practice, down-regulate the immune system at multiple levels in 'shotgun' fashion. The agents described here include: adrenal corticosteroids, azathioprine, cyclophosphamide, chlorambucil, methotrexate, total lymphoid irradiation, plasmapheresis, and intravenous immunoglobulin. 'Selective' immunotherapeutic strategies are designed to interfere with mechanisms intrinsic to the immune system. Agents that are now being used clinically, or are in advanced stages of development include: cyclosporin A, which interferes with synthesis of the cytokine interleukin 2 (IL2); IL2 toxin, which binds to IL2 receptors on activated T cells, is endocytosed, and kills the cells; and CTLA4Ig, which blocks costimulatory molecules, thus preventing full activation of T cells. We have found that combinations of the selective agents may enhance their effectiveness. 'Specific' strategies are designed to inactivate or suppress antigen-specific T cells. Oral administration of autoantigens has been shown to prevent experimental autoimmune diseases specifically, but the conditions required to suppress ongoing autoimmune diseases are capricious, and depend on many factors. Finally, we describe a method that is still in the experimental stage, which is designed to modify the individual's own antigen-presenting cells so that they will target and inactivate antigen-specific T cells, and thereby turn off the specific autoimmune response. Currently available immunosuppressive methods can now be used successfully to treat many autoimmune neuromuscular diseases, and the application of selective and specific immunotherapeutic strategies promises more precise and effective treatment in the future.",
keywords = "anergy, autoimmunity, immune therapy, immunosuppression, myasthenia gravis, neuromuscular diseases, suppression, tolerance",
author = "Drachman, {Daniel B}",
year = "1996",
doi = "10.1002/(SICI)1097-4598(199610)19:10<1239::AID-MUS1>3.0.CO;2-F",
language = "English (US)",
volume = "19",
pages = "1239--1251",
journal = "Muscle and Nerve",
issn = "0148-639X",
publisher = "John Wiley and Sons Inc.",
number = "10",

}

TY - JOUR

T1 - Immunotherapy in neuromuscular disorders

T2 - Current and future strategies

AU - Drachman, Daniel B

PY - 1996

Y1 - 1996

N2 - Autoimmune mechanisms have recently been implicated in the pathogenesis of an increasing number of neuromuscular diseases. Many of these diseases can be treated with immunotherapeutic agents that are currently available-often with striking success. However, lack of specificity and adverse side effects impose limits on the effectiveness of these immunosuppressive treatments. This article reviews the basic principles of autoimmunity and immune tolerance, and outlines strategies that produce (a) generalized immunosuppression; (b) 'selective' immunotherapy; and (c) 'antigen-specific' immunotherapy. General immunosuppressive treatments, which are the ones most commonly used in current practice, down-regulate the immune system at multiple levels in 'shotgun' fashion. The agents described here include: adrenal corticosteroids, azathioprine, cyclophosphamide, chlorambucil, methotrexate, total lymphoid irradiation, plasmapheresis, and intravenous immunoglobulin. 'Selective' immunotherapeutic strategies are designed to interfere with mechanisms intrinsic to the immune system. Agents that are now being used clinically, or are in advanced stages of development include: cyclosporin A, which interferes with synthesis of the cytokine interleukin 2 (IL2); IL2 toxin, which binds to IL2 receptors on activated T cells, is endocytosed, and kills the cells; and CTLA4Ig, which blocks costimulatory molecules, thus preventing full activation of T cells. We have found that combinations of the selective agents may enhance their effectiveness. 'Specific' strategies are designed to inactivate or suppress antigen-specific T cells. Oral administration of autoantigens has been shown to prevent experimental autoimmune diseases specifically, but the conditions required to suppress ongoing autoimmune diseases are capricious, and depend on many factors. Finally, we describe a method that is still in the experimental stage, which is designed to modify the individual's own antigen-presenting cells so that they will target and inactivate antigen-specific T cells, and thereby turn off the specific autoimmune response. Currently available immunosuppressive methods can now be used successfully to treat many autoimmune neuromuscular diseases, and the application of selective and specific immunotherapeutic strategies promises more precise and effective treatment in the future.

AB - Autoimmune mechanisms have recently been implicated in the pathogenesis of an increasing number of neuromuscular diseases. Many of these diseases can be treated with immunotherapeutic agents that are currently available-often with striking success. However, lack of specificity and adverse side effects impose limits on the effectiveness of these immunosuppressive treatments. This article reviews the basic principles of autoimmunity and immune tolerance, and outlines strategies that produce (a) generalized immunosuppression; (b) 'selective' immunotherapy; and (c) 'antigen-specific' immunotherapy. General immunosuppressive treatments, which are the ones most commonly used in current practice, down-regulate the immune system at multiple levels in 'shotgun' fashion. The agents described here include: adrenal corticosteroids, azathioprine, cyclophosphamide, chlorambucil, methotrexate, total lymphoid irradiation, plasmapheresis, and intravenous immunoglobulin. 'Selective' immunotherapeutic strategies are designed to interfere with mechanisms intrinsic to the immune system. Agents that are now being used clinically, or are in advanced stages of development include: cyclosporin A, which interferes with synthesis of the cytokine interleukin 2 (IL2); IL2 toxin, which binds to IL2 receptors on activated T cells, is endocytosed, and kills the cells; and CTLA4Ig, which blocks costimulatory molecules, thus preventing full activation of T cells. We have found that combinations of the selective agents may enhance their effectiveness. 'Specific' strategies are designed to inactivate or suppress antigen-specific T cells. Oral administration of autoantigens has been shown to prevent experimental autoimmune diseases specifically, but the conditions required to suppress ongoing autoimmune diseases are capricious, and depend on many factors. Finally, we describe a method that is still in the experimental stage, which is designed to modify the individual's own antigen-presenting cells so that they will target and inactivate antigen-specific T cells, and thereby turn off the specific autoimmune response. Currently available immunosuppressive methods can now be used successfully to treat many autoimmune neuromuscular diseases, and the application of selective and specific immunotherapeutic strategies promises more precise and effective treatment in the future.

KW - anergy

KW - autoimmunity

KW - immune therapy

KW - immunosuppression

KW - myasthenia gravis

KW - neuromuscular diseases

KW - suppression

KW - tolerance

UR - http://www.scopus.com/inward/record.url?scp=0029788252&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029788252&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-4598(199610)19:10<1239::AID-MUS1>3.0.CO;2-F

DO - 10.1002/(SICI)1097-4598(199610)19:10<1239::AID-MUS1>3.0.CO;2-F

M3 - Article

C2 - 8808649

AN - SCOPUS:0029788252

VL - 19

SP - 1239

EP - 1251

JO - Muscle and Nerve

JF - Muscle and Nerve

SN - 0148-639X

IS - 10

ER -